Literature DB >> 12228881

Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.

Sylvie Retout1, France Mentré, René Bruno.   

Abstract

We address the problem of the choice and the evaluation of designs in population pharmacokinetic studies that use non-linear mixed-effects models. Criteria, based on the Fisher information matrix, have been developed to optimize designs and adapted to such models. We optimize designs under different constraints and evaluate them for a population pharmacokinetics study, within a new phase III trial of enoxaparin, a low molecular weight heparin. To do this, we approximate the expression of the Fisher information matrix for non-linear mixed-effects models including the residual error variance as a parameter to be estimated. We use the Fedorov-Wynn algorithm to minimize the inverse of the determinant of this matrix as required by the D-optimality criterion. Two optimal designs, as well as a design defined by pharmacologists, are evaluated by the simulation of 30 replicated data sets with NONMEM; all designs involve 220 patients with four measurements per patient. We also evaluate the relevance of the standard errors of estimation given from the Fisher information matrix by comparison with those given by NONMEM. The three designs provide more precise population parameter estimates; the optimal design gives the best precision and offers a simple clinical implementation. The expected standard errors given by the information matrix are close to those obtained by NONMEM on the simulation. Moreover, the proposed criterion of D-optimality appears to be a good measure to compare designs for population studies. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12228881     DOI: 10.1002/sim.1041

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  23 in total

1.  Optimization of individual and population designs using Splus.

Authors:  Sylvie Retout; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

2.  Serial correlation in optimal design for nonlinear mixed effects models.

Authors:  Joakim Nyberg; Richard Höglund; Martin Bergstrand; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-03-14       Impact factor: 2.745

3.  Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.

Authors:  Timothy H Waterhouse; Stefanie Redmann; Stephen B Duffull; John A Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 4.  A pragmatic approach to the design of population pharmacokinetic studies.

Authors:  Amit Roy; Ene I Ette
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

5.  Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.

Authors:  Marylore Chenel; Kayode Ogungbenro; Vincent Duval; Christian Laveille; Roeline Jochemsen; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

6.  Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.

Authors:  Andrew Hooker; Paolo Vicini
Journal:  AAPS J       Date:  2005-11-01       Impact factor: 4.009

Review 7.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Informative study designs to identify true parameter-covariate relationships.

Authors:  Phey Yen Han; Carl M J Kirkpatrick; Bruce Green
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-03-27       Impact factor: 2.745

9.  Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.

Authors:  Marylore Chenel; François Bouzom; Leon Aarons; Kayode Ogungbenro
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-01-07       Impact factor: 2.745

10.  Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.

Authors:  François Pierre Combes; Sylvie Retout; Nicolas Frey; France Mentré
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.